Pentoxifylline (PTX) - An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial

European Journal of Ophthalmology

Volumn 14, Issue 4, 2004, Pages 277-283

  Finamor, Francisco Estivallet ^a   Martins, J R M ^a   Nakanami, D ^a   Paiva, E R ^a   Manso, P G ^a   Furlanetto, R P ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Graves' ophthalmopathy; Pentoxifylline

Indexed keywords

PENTOXIFYLLINE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 4143099168     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210401400401     Document Type: Article

References (40)

1. Terwee CB, Dekker FW, Wiersinga WM. Development of a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998; 82: 773-9.
2. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168-99.
3. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1991; 338: 25-8.
4. Salive ME, Guralnik J, Glynn RJ, et al. Association of visual impairment with mobility and physical function. J Am Geriatr Soc 1994; 42: 287-92.
5. Scott IU, Schein OD, West S, et al. Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol 1994; 112: 329-35.
6. Mangione CM, Lee PP, Hays RD. Measurement of visual functioning and health-related quality of life in eye disease and cataract surgery. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven 1996; 1045-51.
7. Lee PP, Spritzer K, Hays RD. The impact of blurred vision on functioning and well-being. Ophthalmology 1997; 104: 390-6.
8. Dallow RL, Netland PA. Management of thyroid ophthalmopathy (Graves' disease). In: Albert DM, Jacobiec FA, eds. Principles and Practice of Ophthalmology: Clinical Practice. Philadelphia: WB Saunders 1994; 1905-22.
9. Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology 1994; 101: 223-30.
10. Bartley GB, Fatourechi V, Kadrmass EF, et al. Long-term follow-up of Graves' ophthalmopathy in an incidence cohort. Ophthalmology 1996; 103: 958-62.
11. Terwee CB, Dekker FW, Wiersinga WM, et al. Facial disfigurement: is it in the eye of the beholder? A study in patients with Graves' ophthalmopathy. Clin Endocrinol 2003; 58: 192-8.
12. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding the pathogenesis and management. Endocr Rev 1993; 14: 747-93.
13. Clarke A. Psychosocial aspects of facial disfigurement: problems, management and the role of a lay-led organization. Psychol Health Med 1999; 4: 127-42.
14. Dropkin MJO, Malgady RG, Strong EW, et al. Scaling disfigurement and dysfunction in postoperative head and neck patients. Head Neck Surg 1983; 6: 559-70.
15. Newell R. Living with disfigurement. Nurs Times 2002; 98: 34-5.
16. Thompson A, Kent G. Adjusting to disfigurement: process involved in dealing with being visibly different. Clin Psychol Rev 2001; 21: 663-82.
17. Kahaly GJ, Hardt J, Egle UT, et al. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002; 12: 237-9.
18. Elkinton JR. Medicine and the quality of life. Ann Intern Med 1996; 64: 710-4.
19. Spilker B. Introduction to the field of quality of life trials. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven 1996; 1-10.
20. Terwee CB, Gerding MN, Wiersinga WM, et al. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol 1999; 52: 875-84.
21. Pinchera A, Wiersinga WM, Glinoer D, et al. Classification of eye changes of Graves' disease. Thyroid 1992; 2: 235-6.
22. Gerding MN, Terwee CB, Wiersinga WM, et al. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcome Study instrument. Thyroid 1997; 7: 885-9.
23. Balazs CS, Kiss E, Farid NR, et al. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. J Clin Endocrinol Metab 1997; 82: 1999-2002.
24. Wall J, Kennerdell JS. Progress in thyroid-associated ophthalmopathy. Autoimmunity 1995; 22: 191-5.
25. Weetman AP. The role of T lymphocytes in thyroid-associated ophthalmopathy. Autoimmunity 1994; 13: 69-77.
26. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol 1994; 40: 67-78.
27. Kahaly G, Hansen C, Winand R, et al. Plasma glucosaminoglycan in endocrine ophthalmopathy. J Endocrinol Invest 1994; 17: 45-55.
28. Kahaly G, Stover C, Schuler M, et al. Glycosaminoglycans in thyroid associated ophthalmopathy. Autoimmunity 1992; 13: 81-9.
29. Balazs CS, Kiss E. Immunological aspects of the effect of pentoxifylline (Trental). Acta Microbiol Immunol Hung 1994; 41: 121-33.
30. Wiersinga WM, Prummel MF. Editorial: Pathogenesis of Graves' ophthalmopathy-current understanding. J Clin Endocrinol Metab 2001; 86: 501-3.
31. Mohler W, Bletz I, Reiser M. Die struktur von ausscheidungs-produkten des 1-Hexyl-3,7-dimethylxanthins. 1. Uber den Metabolimus des 1-Hexyl-3,7- dimethylxanthins. Arch Pharm 1966; 299: 448-56.
32. Desmoulière A, Guoxiong X, Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two tat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999; 30: 621-31.
33. Ramadori G. The stellate cell of the liver. New insights into pathophysiology of an intriguing cell. Virchows Arch B Cell Pathol 1991; 61: 147-58.
34. Pinzani M, Marra F, Failli P, et al. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br J Pharmacol 1996; 119: 1117-24.
35. Isbrucker RA, Peterson TC. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol Appl Pharmacol 1998; 149: 120-6.
36. Chang CC, Chang TC, Chien LF, et al. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema. Acta Endocrinol 1993; 129: 322-7.
37. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997; 47: 9-14.
38. Albuquerque AK, Santos LP. Avanços no Tratamento da Oftalmopatia de Graves. Programa de Atualização Continuada 1999. São Paulo, SP: Departmento de Oftalmologia, UNIFESP/EPM, 1999.
39. Terwee C, Dekker F, Wiersinga WM, et al. Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002; 146: 751-7.
40. Balazs CS, Kiss E, Farid NR. Inhibitory effect of pentoxifylline on HLA-DR and glycosaminoglycan synthesis of retrobulbar fibroblasts induced by interferon gamma. Acta Microbiol Immunol Hung 1997; 44: 173-9.